Retrospective study identifies predictors of immune-related adverse events and outcomes in patients receiving Chinese ICIs, highlighting the role of inflammatory markers.
Background The widespread clinical application of immune checkpoint inhibitors (ICIs) has brought immune-related adverse events (irAEs) to the forefront of oncology management. However, systematic investigations focusing on the efficacy and irAE profiles of ICIs locally developed in China (Chinese ICIs) in real-world settings remain limited. This study aimed to explore predictive factors and outcomes of irAEs in patients predominantly treated with Chinese ICIs. Methods In this single-center retrospective study, 206 patients with solid tumors treated with ICIs between 2020 and 2024 were included, with 87.9% receiving Chinese ICIs. Multivariate regression analyses were conducted to identify predictors of irAEs and factors associated with progression-free survival (PFS). Clinical characteristics, inflammatory biomarkers, cytokine levels, and cardiac function parameters were comprehensively evaluated. Results Younger age (p=0.04) and the brain metastases (p=0.03) were associated with a higher incidence of irAEs. Organ-specific irAEs showed distinct predictors: hepatitis with younger age, hepatitis B virus (HBV) infection, hepatic malignancy, multisystem irAEs, and elevated IL-10; myocarditis with multisystem irAEs, systemic inflammation markers (white blood cell count, WBC; neutrophil-to-lymphocyte ratio, NLR; systemic immune-inflammation index, SII; systemic inflammation response index, SIRI), and cardiac function indicators (left ventricular ejection fraction, LVEF; QRS duration); thyroiditis with multisystem irAEs and reduced IL-6; while pneumonitis with elevated platelet count (PLT) and IL-6. The type of irAEs was not associated with PFS. Conclusions Younger age and brain metastases were associated with a higher incidence of irAEs. Organ-specific irAEs were characterized by distinct sets of clinical and laboratory predictors. Inflammatory markers correlated with poorer PFS. The type of irAEs was not associated with PFS. Chinese ICIs were not independently associated with an increased risk of specific organ toxicities.
No takes yet. Share an insight, caveat, or question.
Kong et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: